Azitra Aktie
WKN DE: A3D8GZ / ISIN: US05479L1044
18.09.2024 16:32:15
|
Azitra's ATR-04 Gets FDA Fast Track Designation For Skin Rash Linked To EGFR Inhibitors
(RTTNews) - Azitra, Inc. (AZTR) Wednesday announced the receipt of Fast Track Designation from the FDA for ATR-04, a topical treatment targeting moderate to severe skin rash linked to Epidermal Growth Factor Receptor inhibitors or EGFRi, and their associated dermal toxicity.
ATR-04 is a live biotherapeutic product featuring an engineered strain of Staphylococcus epidermidis.
Azitra intends to begin a Phase 1/2 clinical trial involving patients with skin toxicity from EGFR inhibitors by the end of 2024.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Azitra Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |